Phase 4 Glaucoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 65 years old who have been diagnosed with open-angle glaucoma or high eye pressure (ocular hypertension)
• People who are currently using the eye drop medication netarsudil 0.02%/latanoprost 0.005% as their only glaucoma treatment, for at least 2 to 6 weeks
• People who are able to switch to netarsudil 0.02%/latanoprost 0.005% for at least 4 weeks before the third study visit, following a recommended break from their previous medication (confirm with trial site)
• People who have noticeable eye redness (rated at least a grade 2 on a standard eye redness scale) after at least 4 weeks on netarsudil 0.02%/latanoprost 0.005%
• People whose vision in the study eye is 20/30 or better when tested with a standard eye chart, even with glasses or contacts
• People who are able to apply eye drops themselves, or who have someone available to help them do so
• People who are willing and able to follow all study procedures and attend all required appointments

Who may not be able to join:

• People with a known allergy or sensitivity to brimonidine, brimonidine tartrate 0.025%, or any ingredient in netarsudil 0.02%/latanoprost 0.005%
• People who are using any other eye drop medications
• People who have an active eye infection, eye inflammation not related to glaucoma treatment, uveitis, iritis, or a condition where the eye lens is absent from birth
• People who have certain eye surface conditions — such as pterygium, pinguecula, chemosis, episcleritis, or scleritis — that could affect how eye redness is measured, in the opinion of the study doctor
• People who have moderate or severe dry eyes
• People who are pregnant, planning to become pregnant, or currently breastfeeding
• People who have used any eye drops that reduce eye redness (other than brimonidine 0.025%) in the past 90 days
• People who have previously had surgical cuts to the eye to lower eye pressure
• People who have had laser treatment for glaucoma (such as SLT or ALT) or minimally invasive glaucoma surgery within the past 6 months
• People who have had any eye surgery (inside or around the eye) within the past 3 months
• People with advanced glaucoma or a high optic nerve damage ratio (greater than 0.8), or whose eye pressure does not respond to netarsudil 0.02%/latanoprost 0.005%
• People who, in the study doctor's judgement, have a significant current or past medical or eye condition that could affect the study results

Important: Always verify eligibility with the trial site directly before applying.